Supernus Pharma (SUPN) Posts Q2 Revenue Beat

Supernus Pharma (NASDAQ: SUPN) reported Q2 GAAP EPS of $0.14, which may not compare to the analyst estimate of $0.37. Revenue for the quarter came in at $170.1 million versus the consensus estimate of $165.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• Elevance (ELV) PT Raised to $482 at Bernstein SocGen